Defining the Optimal Radiation-induced Lymphopenia Metric to Discern Its Survival Impact in Esophageal Cancer

被引:0
作者
Damen, Pim J. J. [1 ,2 ,3 ]
Peters, Max [4 ]
Hobbs, Brian [5 ]
Chen, Yiqing [6 ]
Titt, Uwe [7 ]
Nout, Remi [3 ]
Mohan, Radhe [7 ]
Lin, Steven H. [1 ]
van Rossum, Peter S. N. [1 ,2 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Radiat Oncol, Houston, TX 70030 USA
[2] Amsterdam Univ Med Ctr, Dept Radiat Oncol, Amsterdam, Netherlands
[3] Univ Med Ctr Rotterdam, Erasmus Med Ctr Canc Inst, Dept Radiotherapy, Rotterdam, Netherlands
[4] Radiotherapiegrp, Dept Radiotherapy, Deventer, Netherlands
[5] Univ Texas Austin, Dell Med Sch, Dept Populat Hlth, Austin, TX USA
[6] Univ Texas Hlth Sci Ctr Houston, Dept Biostat & Data Sci, Houston, TX USA
[7] Univ Texas MD Anderson Canc Ctr, Dept Radiat Phys, Houston, TX USA
来源
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2025年 / 122卷 / 01期
关键词
RADIOTHERAPY-RELATED LYMPHOPENIA; NEUTROPHIL-TO-LYMPHOCYTE; LUNG-CANCER; PROGNOSTIC VALUE; CHEMORADIATION; IMMUNOTHERAPY; OUTCOMES; THERAPY; CHEMORADIOTHERAPY; CHEMOTHERAPY;
D O I
10.1016/j.ijrobp.2024.12.014
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: A detrimental association between radiation-induced lymphopenia (RIL) and oncologic outcomes in patients with esophageal cancer has been established. However, an optimal metric for RIL remains undefined but is important for the application of this knowledge in clinical decision-making and trial designs. The aim of this study was to find the optimal RIL metric discerning survival. Methods and materials: Patients with esophageal cancer treated with concurrent chemoradiation therapy (CRT; 2004-2022) were selected. Studied metrics included absolute lymphocyte counts (ALCs) and neutrophil counts-and calculated derivatives-at baseline and during CRT. Multivariable Cox regression models for progression-free survival (PFS) and overall survival (OS) were developed for each RIL metric. The optimal RIL metric was defined as the one in the model with the highest c-statistic. Results: Among 1339 included patients, 68% received photon-based and 32% proton-based CRT (median follow-up, 24.9 months). In multivariable analysis, the best-performing models included "ALC in week 3 of CRT" (corrected c-statistic 0.683 for PFS and 0.662 for OS). At an optimal threshold of <0.5 x 10(3)/mu L (ie, grade >= 3 RIL), ALC in week 3 was significantly associated with PFS (adjusted hazard ratio, 1.64; 95% CI, 1.27-2.13) and OS (adjusted hazard ratio, 1.56; 95% CI, 1.15-2.08), with 5-year PFS of 29% vs 40% and OS of 38% vs 51%, respectively. Conclusions: Reaching grade >= 3 RIL in week 3 of CRT for esophageal cancer is the strongest RIL metric to distinguish survival outcomes. We suggest that this metric should be the target for lymphopenia-mitigating strategies and propose this metric to be included in future trials.
引用
收藏
页码:31 / 42
页数:12
相关论文
共 55 条
[31]   Preliminary Evaluation of PTV Margins for Online Adaptive Radiation Therapy of the Prostatic Fossa [J].
Morgan, Howard E. ;
Wang, Kai ;
Yan, Yulong ;
Desai, Neil ;
Hannan, Raquibul ;
Chambers, Eric ;
Cai, Bin ;
Lin, Mu -Han ;
Sher, David J. ;
Wang, Jing ;
Wang, Andrew Z. ;
Jiang, Steve ;
Timmerman, Robert ;
Park, Chunjoo Justin ;
Garant, Aurelie .
PRACTICAL RADIATION ONCOLOGY, 2023, 13 (04) :E345-E353
[32]   Prognostic value of neutrophil-to-lymphocyte ratio in locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy [J].
Park, Eun Young ;
Kim, Yeon-Sil ;
Choi, Kyu Hye ;
Song, Jin Ho ;
Lee, Hyo Chun ;
Hong, Sook-Hee ;
Kang, Jin-Hyoung .
RADIATION ONCOLOGY JOURNAL, 2019, 37 (03) :166-175
[33]   The Impact of Radiation Therapy on Lymphocyte Count and Survival in Metastatic Cancer Patients Receiving PD-1 Immune Checkpoint Inhibitors [J].
Pike, Luke R. G. ;
Bang, Andrew ;
Mahal, Brandon A. ;
Taylor, Allison ;
Krishnan, Monica ;
Spektor, Alexander ;
Cagney, Daniel N. ;
Aizer, Ayal A. ;
Alexander, Brian M. ;
Rahma, Osama ;
Balboni, Tracy ;
Ott, Patrick A. ;
Hodi, F. Stephen ;
Schoenfeld, Jonathan D. .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 103 (01) :142-151
[34]   Integrating a 1.5 T MRI scanner with a 6 MV accelerator: proof of concept [J].
Raaymakers, B. W. ;
Lagendijk, J. J. W. ;
Overweg, J. ;
Kok, J. G. M. ;
Raaijmakers, A. J. E. ;
Kerkhof, E. M. ;
van der Put, R. W. ;
Meijsing, I. ;
Crijns, S. P. M. ;
Benedosso, F. ;
van Vulpen, M. ;
de Graaff, C. H. W. ;
Allen, J. ;
Brown, K. J. .
PHYSICS IN MEDICINE AND BIOLOGY, 2009, 54 (12) :N229-N237
[35]   Trimodality therapy versus perioperative chemotherapy in the management of locally advanced adenocarcinoma of the oesophagus and oesophagogastric junction (Neo-AEGIS): an open-label, randomised, phase 3 trial [J].
Reynolds, John, V ;
Preston, Shaun R. ;
O'Neill, Brian ;
Lowery, Maeve A. ;
Baeksgaard, Lene ;
Crosby, Thomas ;
Cunningham, Moya ;
Cuffe, Sinead ;
Griffiths, Gareth ;
Parker, Imelda ;
Risumlund, Signe Lenora ;
Roy, Rajarshi ;
Falk, Stephen ;
Hanna, George B. ;
Bartlett, Frederick R. ;
Alvarez-Iglesias, Alberto ;
Achiam, Michael P. ;
Nilsson, Magnus ;
Piessen, Guillaume ;
Ravi, Narayanasamy ;
O'Toole, Dermot ;
Johnston, Ciaran ;
Mcdermott, Raymond S. ;
Turkington, Richard C. ;
Wahed, Shajahan ;
Sothi, Sharmila ;
Ford, Hugo ;
Wadley, Martin S. ;
Power, Derek .
LANCET GASTROENTEROLOGY & HEPATOLOGY, 2023, 8 (11) :1015-1027
[36]   A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization [J].
Sanmamed, Miguel F. ;
Chen, Lieping .
CELL, 2018, 175 (02) :313-326
[37]  
SELLINS KS, 1987, J IMMUNOL, V139, P3199
[38]   COMPARISON OF ACUTE EFFECTS OF RADIATION-THERAPY, INCLUDING OR EXCLUDING THYMUS, ON LYMPHOCYTE SUBPOPULATIONS OF CANCER-PATIENTS [J].
STRATTON, JA ;
BYFIELD, PE ;
BYFIELD, JE ;
SMALL, RC ;
BENFIELD, J ;
PILCH, Y .
JOURNAL OF CLINICAL INVESTIGATION, 1975, 56 (01) :88-97
[39]   Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J].
Sung, Hyuna ;
Ferlay, Jacques ;
Siegel, Rebecca L. ;
Laversanne, Mathieu ;
Soerjomataram, Isabelle ;
Jemal, Ahmedin ;
Bray, Freddie .
CA-A CANCER JOURNAL FOR CLINICIANS, 2021, 71 (03) :209-249
[40]   Effects of Chemotherapy Regimen and Radiation Modality on Hematologic Toxicities in Patients Receiving Definitive Platinum-based Doublet Chemoradiation for Non-Small Cell Lung Cancer [J].
Tang, Chad ;
Lee, Michael S. ;
Gomez, Daniel ;
Levy, Larry B. ;
Zhuang, Yan ;
Lu, Charles ;
Liao, Zhongxing ;
Komaki, Ritsuko .
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2017, 40 (06) :625-630